Pfizer share news, announcements and annual reports
NSE: PFIZERBSE: 500680Pharmaceuticals & BiotechnologySmall Cap
Pfizer Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1966 on BSE, Apr 1999 on NSE
Last close ₹3,638.70down ₹49.10 (1.33%)BSE ₹3,637.90
Share price at the NSE close on 2 Nov 2026. Previous close ₹3,687.80.
2 Nov: open ₹3,687.80, high ₹3,718.20, low ₹3,613.60
52-week range of traded prices to 2 Nov 2026
₹3,589.00Low, 23 Oct 2026₹5,339.00High, 13 Nov 2025
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,646 Cr327th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 22.64
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.96
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.06%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 17.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 21.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 55,74259.3% delivered
Pfizer share news and announcements
658 announcements, routine notices left out, newest first. Page 13 of 14.
Feb 2010
25 Feb · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the year ended on 30-NOV-2009 as follows: Net Sales of Rs. 77160 lacs for year ending on 30-NOV-2009 against Rs. 67771 lacs for the year ending on 30-NOV-2008. Net Profit / (Loss) of Rs. 13718 lacs for the year ending on 30-NOV-2009 against Rs. 29912 lacs for the year ending on 30-NOV-2008.25 Feb · Dividend
Pfizer Ltd. has informed the Exchange that the Board of Directors at its meeting held on February 25, 2010, recommended a Dividend of Rs. 12.50 per Equity Share of Rs.10/- each (125%) for the financial year ended November 30, 2009.25 Feb · Results
Pfizer Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 30-NOV-2009 as follows: Net Sales of Rs. 77227 lacs for year ending on 30-NOV-2009 against Rs. 68170 lacs for the year ending on 30-NOV-2008. Net Profit / (Loss) of Rs. 13712 lacs for the year ending on 30-NOV-2009 against Rs. 29958 lacs for the year ending on 30-NOV-2008.17 Feb · Board meeting
To consider the Audited Financial Results of the Company for the year ended November 30, 2009 and to recommend dividend thereon.
Dec 2009
23 Dec · Results
Pfizer Ltd. has informed the Exchange that "We propose to announce the Audited Financial Results for the financial year ended November 30, 2009 within the 3 months period as stipulated in Clause 41 of the Listing Agreement. Therefore, we will not be publishing the Un-audited Financial Results for the last quarter ended November 30, 2009".
Sep 2009
29 Sep · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-AUG-2009 as follows: Net Sales of Rs. 20484 lacs for quarter ending on 31-AUG-2009 against Rs. 18768 lacs for the quarter ending on 31-AUG-2008. Net Profit / (Loss) of Rs. 4115 lacs for the quarter ending on 31-AUG-2009 against Rs. 3808 lacs for the quarter ending on 31-AUG-2008.29 Sep · Updates
Pfizer Ltd. has informed the Exchange that the Board of Directors of the Company, at its meeting held on September 26, 2009, has, subject to receipt of all requisite consents and approvals from statutory and regulatory authorities pursuant to the applicable provisions of the Companies Act, 1956, approved the Scheme of Amalgamation of Duchem Laboratories Limited (wholly owned subsidiary of Pfizer Limited) and Pfizer Limited. The Scheme is proposed to be effective December 1, 2008. The Transferor Company being the wholly owned subsidiary of Pfizer Limited, no consideration shall be payable to the Transferor Company or its shareholders pursuant to the Amalgamation and the shares held by Pfizer Limited and its nominees in the Transferor Company shall stand cancelled.17 Sep · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 3rd quarter ended August 31, 2009.
Aug 2009
10 Aug · Limited Review Report
Pfizer Ltd. has informed the Exchange that the auditors have conducted the limited review for the un-audited financial results for the quarter and six months ended May 31,2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2009
24 Jul · Sale of shares
As per the guideline on Institutional Transactions in shares issued by Govt. of India during the year 1990, we hereby inform that Life Insurance Corporation of India has sold 4290667 equity shares face value of Rs.10/- of Pfizer Limited @ Rs.830.00 per share20 Jul · Post offer Public announcement
Post offer public announcement as it appeared in the newspapers, with reference to the open offer by Pfizer Investments Netherlands B.V. ("Acquirer") and Pfizer Inc ("PAC") to the equity shareholders of Pfizer Limited ("Target Company") to acquire 10,078,143 equity shares ("Shares"), pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 ("Open Offer"). A copy of the post offer public announcement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jun 2009
27 Jun · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAY-2009 as follows: Net Sales of Rs. 18585 lacs for quarter ending on 31-MAY-2009 against Rs. 16344 lacs for the quarter ending on 31-MAY-2008. Net Profit / (Loss) of Rs. 3129 lacs for the quarter ending on 31-MAY-2009 against Rs. 3792 lacs for the quarter ending on 31-MAY-2008.27 Jun · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 31-MAY-2009 as follows: Net Sales of Rs. 37182 lacs for half year ending on 31-MAY-2009 against Rs. 31381 lacs for the half year ending on 31-MAY-2008. Net Profit / (Loss) of Rs. 7030 lacs for the half year ending on 31-MAY-2009 against Rs. 23081 lacs for the half year ending on 31-MAY-2008.25 Jun · Updates
Supplemental public announcement made on June 25, 2009, with reference to the public announcement made on April 16, 2009 for open offer by Pfizer Investments Netherlands B.V. ("Acquirer") and Pfizer Inc ("PAC") to the equity shareholders of Pfizer Limited ("Target Company") to acquire 10,078,143 equity shares ("Shares"), pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 ("Open Offer"). The supplemental public announcement appears on June 25, 2009 in the newspapers. A copy of the supplemental public announcement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jun · Meeting
Pfizer Ltd. has submitted to the Exchange a copy of the Minutes of the Annual General Meeting held on April 15, 2009. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Jun · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 2nd quarter ended May 31, 2009.1 Jun · Corrigendum
Corrigendum to the public announcement made on June 01, 2009. With reference to the public announcement made on April 16, 2009, Open Offer by Pfizer Investments Netherlands B.V. ("Acquirer") and Pfizer Inc ("PAC") to the equity shareholders of Pfizer Limited ("Target Company") to acquire 10,078,143 equity shares ("Shares"), pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 ("Open Offer"). A copy of the corrigendum to the public announcement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2009
16 Apr · Public Announcement-Open Offer
Public Announcement ("PA") being issued by HSBC Securities & Capital Markets (India) Private Limited ("HSCI" or the "Manager to the Offer") for and on behalf of Pfizer Investments Netherlands B.V. ("Acquirer") and Pfizer Inc. ("PAC"), to the shareholders of Pfizer Limited ("Pfizer India" or "Target Company") pursuant to and in compliance with among others, Regulation 11(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 1997 and subsequent amendments thereto ("SEBI (SAST) Regulations" or the "Regulations"). The Acquirer along with the PAC is making a voluntary offer (the "Offer" or "Open Offer") to the public shareholders of Pfizer India for acquiring up to 10,078,143 fully paid up equity shares of the Target Company (the "Offer Size") constituting 33.77% of the Voting Capital (as defined in Clause 1.3 of the PA) of the Target Company at a price of Rs. 675 per equity share (the "Offer Price"). This Offer is being made to all the public shareholders of the Target Company and is not conditional on any minimum level of acceptance by the public shareholders of the Target Company. The Date of opening of the Offer is June 10, 2009 & Date of closing of the Offer is June 29, 2009. A copy of the Public Announcement-Open Offer shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.13 Apr · Business
Pfizer Ltd. has informed the Exchange regarding press release dated April 13, 2009, titled "Pfizer To Make a Tender offer To Increase Stake in Pfizer Limited; This release is neither an offer to purchase nor a solicitation of an offer to sell shares of Pfizer Limited". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
19 Mar · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 1st quarter ended February 28, 2009.13 Mar · Meeting
Pfizer Ltd. has informed the Exchange that Register of Members and the Share Transfer Books of the Company will remain closed from April 06, 2009 to April 15, 2009 (both days inclusive) for the purpose of payment of Dividend. The Dividend, if declared at the forthcoming Annual General Meeting, will be paid on April 30, 2009. The Annual General Meeting of the Company is scheduled to be held on April 15, 2009.
Jan 2009
30 Jan · Results
Pfizer Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 30-NOV-2008 as follows: Net Sales of Rs. 68170 lacs for year ending on 30-NOV-2008 against Rs. 67669 lacs for the year ending on 30-NOV-2007. Net Profit / (Loss) of Rs. 29958 lacs for the year ending on 30-NOV-2008 against Rs. 34000 lacs for the year ending on 30-NOV-2007.30 Jan · Dividend
Pfizer Ltd. has informed the Exchange that the Board of Directors at its meeting held on January 30, 2009 recommended a dividend of Rs. 12.50 per Equity Share of Rs. 10/- each (125%) for the financial year ended November 30, 2008.22 Jan · Board meeting
To consider the Audited Statement of Accounts of the Company for the year ended November 30, 2008 and to recommend dividend thereon.
Dec 2008
10 Dec · Results
Pfizer Ltd. has informed the Exchange that the Company propose to announce the Audited Financial Results for the financial year ended November 30, 2008 within 3 months period as stipulated in Clause 41 of the Listing Agreement. Therefore, the Company will not be publishing the Un-audited Financial Results for the last quarter ended November 30, 2008.
Sep 2008
30 Sep · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-AUG-2008 as follows: Net Sales of Rs. 18768 lacs for quarter ending on 31-AUG-2008 against Rs. 17565 lacs for the quarter ending on 31-AUG-2007. Net Profit / (Loss) of Rs. 3808 lacs for the quarter ending on 31-AUG-2008 against Rs. 3083 lacs for the quarter ending on 31-AUG-2007.22 Sep · Board meeting
Inter-alia to consider and approve the Unaudited Financial Results for the 3rd quarter ended August 31, 2008.
Jun 2008
30 Jun · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 31-MAY-2008 as follows: Net Sales of Rs. 31381 lacs for half year ending on 31-MAY-2008 against Rs. 31967 lacs for the half year ending on 31-MAY-2007. Net Profit / (Loss) of Rs. 23081 lacs for the half year ending on 31-MAY-2008 against Rs. 28603 lacs for the half year ending on 31-MAY-2007.30 Jun · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAY-2008 as follows: Net Sales of Rs. 16344 lacs for quarter ending on 31-MAY-2008 against Rs. 16467 lacs for the quarter ending on 31-MAY-2007. Net Profit / (Loss) of Rs. 3792 lacs for the quarter ending on 31-MAY-2008 against Rs. 25776 lacs for the quarter ending on 31-MAY-2007.20 Jun · Board meeting
Inter-alia to consider the Unaudited Financial Results for the 2nd quarter ended May 31, 2008.
May 2008
16 May · Meeting
Pfizer Ltd. has submitted to the Exchange a copy of the Minutes of the Annual General Meeting of the Shareholders of the Company held on April 15, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Apr 2008
29 Apr · Management
Pfizer Ltd. has informed the Exchange that: "Mr. Yugesh Goutam, Executive Director, Human Resources, has resigned from the Board of Pfizer Ltd. effective from the close of business hours of 28th April, 2008".
Mar 2008
31 Mar · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 29-FEB-2008 as follows: Net Sales of Rs. 15037 lacs for quarter ending on 29-FEB-2008 against Rs. 15500 lacs for the quarter ending on 28-FEB-2007. Net Profit / (Loss) of Rs. 19289 lacs for the quarter ending on 29-FEB-2008 against Rs. 2827 lacs for the quarter ending on 28-FEB-2007.24 Mar · Board meeting
To consider the Unaudited Financial Results of the Company for the 1st Quarter ended February 29, 2008.19 Mar · Meeting
Pfizer Ltd. has informed the Exchange that Register of Members and the Share Transfer Books of the Company will remain closed from April 07, 2008 to April 15, 2008 (both days inclusive) for the purpose of determining the eligibility of payment of Dividend. The Dividend, if declared at the forthcoming Annual General Meeting, will be paid on or after April 21, 2008. The Annual General Meeting of the Company is scheduled to be held on April 15, 2008.
Feb 2008
25 Feb · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the year ended on 30-NOV-2007 as follows: Net Sales of Rs. 67266 lacs for year ending on 30-NOV-2007 against Rs. 66235 lacs for the year ending on 30-NOV-2006. Net Profit / (Loss) of Rs. 33893 lacs for the year ending on 30-NOV-2007 against Rs. 10573 lacs for the year ending on 30-NOV-2006.25 Feb · Dividend
Pfizer Ltd. has informed the Exchange that the Board of Directors at its meeting held on February 25, 2008 recommended a total Dividend of Rs. 27.50 (275%) per Equity share of Rs. 10/- each, for the financial year ended November 30, 2007, being normal dividend of Rs. 12.50 (125%) per share and additional dividend of Rs. 15/- (150%) per equity share, in view of sale of four Consumer Healthcare Brands to Johnson & Johnson Limited.25 Feb · Results
Pfizer Ltd. has informed the Exchange regarding the consolidated Results for the year ended on 30-NOV-2007 as follows: Net Sales of Rs. 67669 lacs for year ending on 30-NOV-2007 against Rs. 66679 lacs for the year ending on 30-NOV-2006. Net Profit / (Loss) of Rs. 34000 lacs for the year ending on 30-NOV-2007 against Rs. 10633 lacs for the year ending on 30-NOV-2006.25 Feb · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 30-NOV-2007 as follows: Net Sales of Rs. 17734 lacs for quarter ending on 30-NOV-2007. Net Profit / (Loss) of Rs. 2206 lacs for the quarter ending on 30-NOV-2007.18 Feb · Board meeting
To consider the Audited Statement of Accounts of the Company for the year ended November 30, 2007 and to recommend dividend thereon.
Dec 2007
31 Dec · Updates
Pfizer Ltd. has informed the Exchange vide its letter dated December 31, 2007, that "The Board of Directors has at its meeting held today, granted its approval to the transfer to Johnson & Johnson Limited, of the exclusive license that Pfizer Limited holds in respect of the trademarks relating to Benadryl, Caladryl, Benylin and Listerine and certain assets related thereto, for a total consideration of Rs.214,85,10,000/- (Rupees Two Hundred and Fourteen Crores Eighty Five Lakhs and Ten Thousand only) and in connection therewith the execution of the Asset Transfer Agreement. The Board of Directors also granted its approval to Pfizer Limited providing to Johnson & Johnson Limited, certain transitional services and in connection therewith the execution of the Transitional Services Agreement".14 Dec · Results
Pfizer Ltd. has informed the Exchange that the company will publish the Audited Financial Results for the financial year ended November 30, 2007 within the 3 months period.
Sep 2007
24 Sep · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-AUG-2007 as follows: Net Sales of Rs. 17565 lacs for quarter ending on 31-AUG-2007 against Rs. 17845 lacs for the quarter ending on 31-AUG-2006. Net Profit / (Loss) of Rs. 3083 lacs for the quarter ending on 31-AUG-2007 against Rs. 2807 lacs for the quarter ending on 31-AUG-2006.13 Sep · Board meeting
Inter-alia to consider the Unaudited Financial Results for the 3rd quarter ended August 31, 2007.3 Sep · Management
Pfizer Ltd. has informed the Exchange that "Mr. K. Subharaman, Company Secretary, has ceased to be in the employment of the Company with effect from the close of business on August 31, 2007. Accordingly, he also ceased to be the Compliance Officer of the Company with effect from the said date. Mr. Prajeet Nair has been appointed as the Company Secretary with effect from September 1, 2007. Mr. Nair will act as the Compliance Officer of the Company with effect from the said date".
Aug 2007
7 Aug · Limited Review Report
Pfizer Ltd. has informed the Exchange that the auditor's have conducted the limited review of the unaudited financial results for the quarter ended May 31, 2007. The copy of the same shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2007
3 Jul · Management
Pfizer Ltd. has informed the Exchange that the Board of Directors in its meeting held on June 28, 2007 have appointed Mr. Yugesh Goutam, Senior Director-Human Resources (HR) as Additional Director on the Board of Pfizer Ltd.
Jun 2007
28 Jun · Miscellaneous
Pfizer Ltd. has submitted to the Exchange Unaudited Financial Results for the second quarter / half year ended May 31, 2007 which inter-alia mentions that - (A) Other Income includes Service Income for the three months and six months ended May 31, 2007 of Rs.588 lakhs and Rs.1109 lakhs respectively (corresponding three months and six months in the previous year - Rs.581 lakhs and Rs.1337 lakhs respectively). (B) During the current quarter ended May 31, 2007, the Company has executed the Sale Deed for the transfer of its Chandigarh property comprising of land, buildings, movable Plant and Machineries and other assets, on "as is where is" basis for a total consideration of Rs.27800 lakhs. The Company has received full consideration. The profit on sale amounting to Rs.27369 lakhs has been recognized in the current quarter ended May 31, 2007 and included under the head "Other Income". During the corresponding quarter in the previous year, profit on sale of Hyderabad property amounting to Rs.1181 lakhs has been accounted under the head "Other Income".28 Jun · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the half year ended on 31-MAY-2007 as follows: Net Sales of Rs. 31967 lacs for half year ending on 31-MAY-2007 against Rs. 31305 lacs for the half year ending on 31-MAY-2006. Net Profit / (Loss) of Rs. 28603 lacs for the half year ending on 31-MAY-2007 against Rs. 6066 lacs for the half year ending on 31-MAY-2006.28 Jun · Results
Pfizer Ltd. has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAY-2007 as follows: Net Sales of Rs. 16467 lacs for quarter ending on 31-MAY-2007 against Rs. 16707 lacs for the quarter ending on 31-MAY-2006. Net Profit / (Loss) of Rs. 25776 lacs for the quarter ending on 31-MAY-2007 against Rs. 3589 lacs for the quarter ending on 31-MAY-2006.